Brachytherapy

Table of content 

1.    Introduction and summary
2.    Executive summary table
2.1.    High dose brachytherapy in out-patient settings
2.2.    Implantation of seeds for LDR brachytherapy for prostate cancer in hospital
3.    Contents
4.    Abbreviations
5.    Methodology
6.    What’s new
7.    Reimbursement analysis in Austria
7.1.    Overview of the reimbursement system
7.2.    Reimbursement for brachytherapy
7.2.1.    Procedure coding
7.2.2.    Diagnosis coding
7.2.3.    Payment mechanism and reimbursement tariffs
7.2.4.    Policy considerations
8.    Reimbursement analysis in Belgium
8.1.    Overview of the reimbursement system
8.2.    Reimbursement for brachytherapy
8.2.1.    Procedure coding
8.2.2.    Payment mechanism and reimbursement tariffs
8.2.3.    Policy considerations
9.    Reimbursement analysis in Denmark
9.1.    Overview of the reimbursement system
9.2.    Reimbursement for brachytherapy
9.2.1.    Procedure coding 
9.2.2.    Diagnosis coding
9.2.3.    Payment mechanism and reimbursement tariffs
9.2.4.    Policy considerations
10.    Reimbursement analysis in England
10.1.    Overview of the reimbursement system
10.2.    Reimbursement for brachytherapy
10.2.1.    Procedure coding 
10.2.2.    Diagnosis coding
10.2.3.    Payment mechanism and reimbursement tariffs
10.2.4.    Policy considerations 
10.2.4.1.    Specifics of commissioning of the procedure
10.2.4.2.    Health technology assessments by NICE
11.    Reimbursement analysis in Finland
11.1.    Overview of the reimbursement system
11.2.    Reimbursement for brachytherapy
11.2.1.    Procedure coding 
11.2.2.    Diagnosis coding
11.2.3.    Payment mechanism and reimbursement tariffs
11.2.4.    Policy considerations
12.    Reimbursement analysis in France
12.1.    Overview of the reimbursement system
12.2.    Reimbursement for brachytherapy
12.2.1.    Procedure coding 
12.2.2.    Diagnosis coding
12.2.3.    Payment mechanism and reimbursement tariffs
12.2.4.    Policy considerations by HAS
13.    Reimbursement analysis in Germany
13.1.    Overview of the reimbursement system
13.2.    Reimbursement for brachytherapy
13.2.1.    Procedure coding 
13.2.2.    Diagnosis coding
13.2.3.    Payment mechanism and reimbursement tariffs
13.2.4.    Policy considerations by G-BA
14.    Reimbursement analysis in Italy
14.1.    Overview of the reimbursement system
14.2.    Reimbursement for brachytherapy
14.2.1.    Procedure coding at national level
14.2.2.    Procedure coding at regional level (Emilia-Romagna, Lombardy, Veneto regions)
14.2.3.    Diagnosis coding
14.2.4.    Payment mechanism and reimbursement tariffs at national level
14.2.5.    Payment mechanism and reimbursement tariffs at regional level
14.2.6.    Policy considerations
15.    Reimbursement analysis in the Netherlands
15.1.    Overview of the reimbursement system
15.2.    Reimbursement for brachytherapy
15.2.1.    Procedure coding 
15.2.2.    Diagnosis coding
15.2.3.    Payment mechanism and reimbursement tariffs
15.2.4.    Policy considerations by Dutch Healthcare Institute (ZIN)
16.    Reimbursement analysis in Norway
16.1.    Overview of the reimbursement system
16.2.    Reimbursement for brachytherapy
16.2.1.    Procedure coding 
16.2.2.    Diagnosis coding
16.2.3.    Payment mechanism and reimbursement tariffs
16.2.4.    Policy considerations 
17.    Reimbursement analysis in Sweden
17.1.    Overview of the reimbursement system
17.2.    Reimbursement for brachytherapy
17.2.1.    Procedure coding 
17.2.2.    Diagnosis coding
17.2.3.    Payment mechanism and reimbursement tariffs
17.2.4.    Policy considerations 
18.    Reimbursement analysis in Switzerland
18.1.    Overview of the reimbursement system
18.2.    Reimbursement for brachytherapy
18.2.1.    Procedure coding 
18.2.2.    Diagnosis coding
18.2.3.    Payment mechanism and reimbursement tariffs
18.2.4.    Policy considerations
19.    Summary of procedure codes
20.    Summary of reimbursement codes and tariffs
21.    Disclaimer